Navigation Links
NeurogesX Announces Presentation of Positive Phase 3 Clinical Data,at the Second International Congress on Neuropathic Pain Meeting,(NeuPSIG)

SAN CARLOS, Calif., June 07, 2007 /PRNewswire-FirstCall/ -- NeurogesX, Inc. announced today the presentation of clinical data from a positive Phase 3 trial in postherpetic neuralgia (PHN). Misha-Miroslav Backonja, M.D., Professor of Neurology at University of Wisconsin in Madison and lead academic investigator in the NeurogesX trial, plans to present the results of the study in a June 8 poster session at the Second International Congress on Neuropathic Pain in Berlin, Germany. Dr. Backonja's poster presentation is based on an abstract titled, "Localized Treatment with NGX- 4010 Significantly Reduced Pain for up to 12 Weeks: Results of A Randomized, Double-Blind, 12-Week Controlled Study in Postherpetic Neuralgia Patients."

The study evaluated the effect of a single application of NGX-4010, the Company's novel dermal patch, on pain due to PHN. The primary endpoint in this Phase 3 trial was achieved, demonstrating a statistically significant reduction in pain over an 8-week period (NGX-4010, -29.6% vs. control, -19.9%; p = 0.001). The reduction of pain was sustained over 12 weeks (NGX-4010, -29.9% vs. control, -20.4%; p=0.0016).

"The results of this pivotal Phase 3 trial demonstrate NGX-4010 is effective both alone and in combination with other neuropathic pain medications for the treatment of PHN," said Dr. Backonja. "We believe that NGX-4010's unique profile has the potential to provide a meaningful therapeutic alternative to traditional therapies that need to be taken daily, most of which have systemic side effects."

According to the Centers for Disease Control, there are approximately 1.0 million cases of shingles in the United States each year, and approximate one in five shingles sufferers go on to develop PHN. People with PHN experience pain and increased sensitivity of the skin that can persist for many years.

NeurogesX plans to complete a confirmatory Phase 3 trial in PHN in t he second half of 2007 and expects to submit marketing applications to the European Medicines Agency in 2007 for European Union approval and to the U.S. Food and Drug Administration (FDA) in 2008.

About NGX-4010

NGX-4010 is a physician-administered dermal patch containing a TRPV1 agonist which targets small nerve fibers in the skin at the site of neuropathic pain. Clinical studies to date indicate that a single 30 or 60 minute administration of NGX-4010 may result in clinically meaningful pain relief for up to 12 weeks. NGX-4010 is designed to work locally in the skin without significant absorption into the bloodstream, possibly allowing users to avoid the side effects of current treatment options, such as anti- convulsants, anti-depressants and opioids.

About NeurogesX

NeurogesX is a biopharmaceutical company focused on developing novel pain management therapies. The Company's initial focus is on chronic peripheral neuropathic pain, including PHN, painful HIV-distal sensory polyneuropathy (HIV-DSP), and diabetic neuropathy. NeurogesX's late stage product portfolio is led by product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions that offers significant advantages over other pain therapies. Two Phase 3 trials with NGX-4010 have been completed and have met their primary endpoints, one in PHN and one in HIV-DSP. NGX-4010 has been granted Orphan Drug and Fast Track Status for HIV-DSP by the FDA.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, statements relating to the filing for regulatory approvals and the ti ming of such filings; the successful completion of clinical trials with respect to NeurogesX' lead product candidate, NGX-4010; and market acceptance of NGX- 4010. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, patient enrollment for clinical trials may be difficult; past results of clinical trials may not be indicative of future clinical trials results; NeurogesX' product candidate may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA or European regulatory approval; physician or patient reluctance to use NGX-4010, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in clinical development, obtaining regulatory approval, market acceptance and commercialization of NGX-4010. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.


    Stephen Ghiglieri

    (650) 508-2116

    The Ruth Group

    Investors / Media

    Stephanie Carrington / Janine McCargo

    (646) 536-7017 / 7033


CONTACT: Stephen Ghiglieri of NeurogesX, +1-650-508-2116; or Investors,Stephanie Carrington, +1-646-536-7017, , orMedia, Janine McCargo, +1-646-536-7033, , both ofThe Ruth Group

Ticker Symbol: (NASDAQ-NMS:NGSX)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
(Date:6/24/2016)... 2016 Dublin ... addition of the " Global Markets for Spectroscopy ... This report focuses on the ... review, including its applications in various applications. The report ... includes three main industries: pharmaceutical and biotechnology, food and ...
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented ... in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, ...
(Date:6/24/2016)... Maryland (PRWEB) , ... June 24, 2016 , ... ... Angels is actively feeding the Frederick area economy by obtaining investment capital for ... over the past 2½ years that have already resulted in more than a ...
(Date:6/24/2016)... Gaithersburg, MD (PRWEB) , ... June 24, 2016 ... ... and protocols for human induced pluripotent stem (iPS) cells and other difficult to ... PluriQ™ G9™ Cloning Medium. The PluriQ™ G9™ Gene Editing System is ...
Breaking Medicine News(10 mins):